Stock
A lot has happened in the stock market since Liberation Day, keeping us on our toes. Volatility has declined significantly, stocks have bounced back...
Hi, what are you looking for?
QQQ and tech ETFs are leading the surge off the April low, but there is another group leading year-to-date. Year-to-date performance is important because...
A lot has happened in the stock market since Liberation Day, keeping us on our toes. Volatility has declined significantly, stocks have bounced back...
Most religions of the world have the fundamental beliefs that are strikingly similar to the Ten Commandments. History has taught humanity that life does...
Good morning and welcome to this week’s Flight Path. We saw another strong week of blue “Go” bars for the equity index. Treasury bond prices...
The markets consolidated throughout the past week, which was a shortened one, with Monday, June 17th being a holiday on account of Bakri Eid....
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
The markets consolidated throughout the past week, which was a shortened one, with Monday, June 17th being a holiday on account of Bakri Eid....
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
The markets consolidated throughout the past week, which was a shortened one, with Monday, June 17th being a holiday on account of Bakri Eid....
Extremely heavy volume that accompanies a gap higher and a reversing candle after a lengthy uptrend is typically a sign of buyers’ exhaustion and...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets....
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...